Treatment
Luspatercept clinical trials
We’re tracking 18 recruiting studies that include Luspatercept, each written for real people, not researchers, below.
Recruiting studies
- NCT07338344RecruitingPhase 2
Luspatercept with thalidomide for beta-thalassemia patients
This study tests whether a combination of two drugs, luspatercept and thalidomide, can help people with beta-thalassemia who need regular blood transfusions. It aims to reduce the number of transfusions needed.
Shenzhen, GuangdongAges 18–75 - NCT07215975Recruiting
Luspatercept for adults with transfusion-dependent beta-thalassemia
This study looks at how well a medication called Luspatercept works for adults with transfusion-dependent beta-thalassemia, a blood condition that requires regular blood transfusions. Researchers want to understand how it helps people in the Middle East.
Al JahraAges 18 years+ - NCT05664737RecruitingPhase 2
Luspatercept for adults with alpha thalassemia
This study tests a medicine called luspatercept to see if it can help people with alpha thalassemia need fewer blood transfusions. It is for adults and some teens with this condition.
Halifax, Nova ScotiaAges 12 years+ - NCT05925504RecruitingPhase 2
Lowering luspatercept dose for lower-risk myelodysplastic anemia
This Phase 2 study tests whether gradually lowering the dose of luspatercept can help people with lower-risk myelodysplastic syndromes (MDS) who have anemia. It may help reduce side effects while still improving blood counts or symptoms.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT07725497RecruitingPhase 2
Luspatercept for anemia from chronic kidney disease
This trial tests a drug called luspatercept to see if it can raise hemoglobin levels in people with anemia caused by chronic kidney disease. It's for those whose current treatments aren't working well or who cannot use them.
Basking Ridge, New JerseyAges 18 years+ - NCT04064060RecruitingPhase 3
Long-term safety follow-up for luspatercept study participants
This trial studies the long-term safety of luspatercept (ACE-536) in people who already took part in an earlier luspatercept study. It mainly helps doctors better understand ongoing side effects and overall safety over time.
Los Angeles, CaliforniaAges 18 years+ - NCT05181735RecruitingPhase 1/Phase 2
Testing luspatercept for low-risk MDS with low hemoglobin
This Phase 1/2 study tests luspatercept combined with another approach in people with low-risk myelodysplastic syndrome (MDS) who are not responding to or cannot use ESA (a common anemia treatment). It may help improve anemia (low hemoglobin), reduce transfusions, and control the disease if you fit the specific criteria.
AmiensAges 18 years+ - NCT05384691RecruitingPhase 2
Luspatercept for anemia in lower-risk MDS not needing transfusions
This Phase 2 trial studies whether luspatercept can improve anemia in people with lower-risk myelodysplastic syndrome (MDS) who do not currently need red-blood-cell transfusions. It’s also looking to see if the benefit is similar whether or not you have ring sideroblasts.
BerlinAges 18 years+ - NCT05924100RecruitingPhase 2
Luspatercept for lower red blood counts in MDS with del5q
This Phase 2 trial studies luspatercept to improve anemia (low red blood cells) in people with MDS that has a del5q change. It also checks safety, especially for people who need red blood cell transfusions and have not benefited from prior standard treatments.
AlessandriaAges 18 years+ - NCT06073860Recruiting
Safety study of Luspatercept for MDS or thalassemia in Korea
This study is checking the safety of a drug called Luspatercept (brand name Reblozyl) for people in Korea who have myelodysplastic syndrome (a blood disorder) or beta-thalassemia (a type of inherited anemia). It is designed to monitor how safe the drug is when used as prescribed by your doctor.
SeoulAges 19 years+ - NCT06517875RecruitingPhase 2
Testing momelotinib plus luspatercept for transfusion-dependent myelofibrosis
This study tests a combination of two drugs, momelotinib and luspatercept, for people with myelofibrosis who need regular red blood cell transfusions. The goal is to see if the combination can reduce transfusion needs and improve symptoms.
Ann Arbor, MichiganAges 18 years+ - NCT06788691RecruitingPhase 2
Luspatercept for low blood counts with gene change (CCUS)
This trial tests a drug called luspatercept for people with a condition called CCUS, where they have low blood counts and a gene change. The goal is to see if the drug can improve blood counts and reduce symptoms like fatigue or bleeding risk.
New York, New YorkAges 18 years+ - NCT07096297RecruitingPhase 2
Testing two drugs for lower-risk MDS
This trial is testing whether a combination of two drugs, luspatercept and darbepoetin alfa, can help people with lower-risk myelodysplastic syndromes (MDS) who need frequent red blood cell transfusions. The goal is to see if the combination reduces their need for transfusions.
New Haven, ConnecticutAges 18 years+ - NCT07362095RecruitingPhase 1/Phase 2
Luspatercept for anemia after a stem cell transplant
This study tests a drug called luspatercept to see if it can help people who have low red blood cells (anemia) after a stem cell transplant for leukemia. It may improve your energy and reduce the need for blood transfusions.
Guangzhou, GuangdongAges 18–70 - NCT07663864RecruitingPhase 1/Phase 2
Luspatercept for anemia after AML treatment
This trial tests if luspatercept can help improve red blood cell counts in people with a certain type of acute myeloid leukemia (AML) who have mild to moderate anemia after intensive chemotherapy. It is for patients with a lower-risk form of AML who have completed 1–3 cycles of high-dose consolidation therapy.
Guangzhou, GuangdongAges 18–60 - NCT05564390RecruitingPhase 2
MyeloMATCH screening to match you to AML or MDS treatment
This study screens people with newly suspected acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) to see which treatment approach fits best—either a specific study treatment or standard care. It may help by directing you to the right option and by sharing your blood/bone marrow samples for research.
Birmingham, AlabamaAges 18 years+ - NCT05931718Recruiting
Track diagnosis and treatment in autoimmune blood count disorders
This study follows adults with autoimmune blood problems like autoimmune hemolytic anemia, immune thrombocytopenia, and autoimmune/neutropenia to see how diagnosis and care work over time. You may be asked to complete follow-up visits for up to 3 years.
MilanAges 18 years+ - NCT04143724RecruitingPhase 2
Luspatercept for children with beta-thalassemia
This study tests a medicine called luspatercept to see if it safely helps children with beta-thalassemia need fewer blood transfusions or keep their hemoglobin levels stable. It is for children aged 6 to 17 who either get regular transfusions or have low hemoglobin and few transfusions.
Los Angeles, CaliforniaAges 6–17
What Luspatercept is being studied for
Conditions with recruiting Luspatercept studies.
Common questions
- Are there clinical trials studying Luspatercept?
- Yes. Clin2 currently lists 18 recruiting studies that include Luspatercept, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Luspatercept trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Luspatercept an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Luspatercept or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.